The eradication of solid tumors by chimeric antigen receptor (CAR) T cells requires dynamic therapies capable of outlasting an immune suppressive tumor microenvironment (TME). However, biological barriers—including rapid exhaustion, poor expansion, and loss of stem-like memory—quickly neutralize these therapies1. Becau...
Rupesh H. Amin, Kevin G. Haworth, H. Moffett et al.· bioRxiv· 0 citations
Cytokines mediate cell-cell communication to coordinate immune responses and hold clinical promise as immunotherapies1–3. While natural cytokines are exquisitely regulated by immune cells, engineered cytokines have not yet matched this sophisticated regulation, limiting clinical efficacy and safety4,5. IL-2 is an impor...
H. Moffett, Brian D. Weitzner, Michelle M. Lissner et al.· bioRxiv· 0 citations
OutLAST Regulators are designed proteins that reprogram critical T cell signaling pathways to enhance functional persistence and are implemented as compact genetic modules compatible with standard viral vectors and cell therapy manufacturing processes, creating a powerful platform for programming new functions into enh...
S. Boyken, Sean A. Merillat, Robert A. Langan et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
